Материалы. Статьи

Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Yolanda Blanco MDa, DrAlbert Saiz MDa, Enric Carreras MDb and Francesc Graus MD. The Lancent Neurology. Volume 4, Issue 1 , January 2005, Pages 54-63 (PDF-формат)
Services of Neurology, Hematology, Hospital Cl'nic, Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
Bone Marrow Transplantation Unit, Hematology, Hospital Cl'nic, Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
Available online 22 December 2004.
Intense immunosupression followed by autologous haematopoietic-stem-cell transplantation (HSCT) is being assessed as a potential treatment for patients with severe multiple sclerosis (MS). The treatment was developed from research that showed autologous HSCT was as effective as allogeneic HSCT in the treatment of experimental autoimmune encephalomyelitis. The treatment is thought to eradicate the defective immune system, and the infused haematopoietic stem cells reconstitute an immune system that is more tolerant to the nervous system. About 250 patients with MS have been treated with autologous HSCT as part of phase I and phase II open trials. Autologous HSCT seems feasible in MS and assessment with clinical and MRI measures suggests it induces a profound and long-lasting suppression of inflammation. The course of MS seems to be stabilised after autologous HSCT, especially in ambulatory patients with evidence of active disease. Autologous HSCT deserves further study in randomised controlled trials.

Mobilized Autologous Stem Cells in the SCI Treatment
Jornal of the Neurological Sciences. Volume 238, Suppl.1 November 15 2005.
Abstracts of the XVIIIth World Congress of Neurology
5-11 November 2005, Sydney, Australia. (Download presentation (iscitt.rar 1,78 Mb)
Bryukhovetski A.S., Yaryghin V.N., Mentkevich G.L., Dolgopolov I., Mheidze D.M., Zaytsev A.Y., Yevseyev N.G.